{"id":"NCT00770562","sponsor":"Hoffmann-La Roche","briefTitle":"A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)","officialTitle":"A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2008-10-10","resultsPosted":"2014-10-22","lastUpdate":"2014-10-22"},"enrollment":103,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"rituximab","otherNames":["MabThera/Rituxan"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Dexamethasone","type":"ACTIVE_COMPARATOR"},{"label":"Dexamethasone plus Rituximab","type":"EXPERIMENTAL"}],"summary":"This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP. The anticipated time on study treatment is \\<3 months, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With a Sustained Response","timeFrame":"Week 24","effectByArm":[{"arm":"Arm A: Dexamethasone","deltaMin":36,"sd":null},{"arm":"Arm B: Dexamethasone + Rituximab","deltaMin":63,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":22,"countries":["Italy"]},"refs":{"pmids":["20130241"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Pyrexia","Headache","Cough","Abdominal pain upper","Asthenia"]}}